Genmab reports $3.96 billion in DARZALEX sales for first quarter 2026

Genmab A/S (NASDAQ: GMAB) announced that worldwide net sales of DARZALEX (daratumumab) totaled $3.964 billion in the first quarter of 2026, according to data reported by Johnson & Johnson.

The sales figures include both intravenous and subcutaneous formulations of the cancer treatment. Net sales in the United States reached $2.208 billion, while international markets generated $1.756 billion in revenue.

Genmab receives royalties on the worldwide net sales of DARZALEX under an exclusive worldwide license agreement with Johnson & Johnson's Janssen Biotech subsidiary. The agreement covers development, manufacturing and commercialization of daratumumab.

The subcutaneous version is marketed as DARZALEX FASPRO in the United States and contains daratumumab and hyaluronidase-fihj. Johnson & Johnson handles global commercialization of both the intravenous and subcutaneous products.

Copenhagen-based Genmab is a biotechnology company focused on antibody medicines for cancer and other diseases. The company was established in 1999 and maintains operations across North America, Europe and Asia Pacific.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• A.O. Smith executive chairman to retire, CEO to assume chairman role
• Nakamoto closes healthcare clinics, completes shift to Bitcoin